Zobrazeno 1 - 10
of 39
pro vyhledávání: '"Johanne Bouthillier"'
Autor:
Alexandre Parks, Xavier Charest-Morin, Michael Boivin-Welch, Johanne Bouthillier, Francois Marceau
Publikováno v:
PeerJ, Vol 3, p e1314 (2015)
The proton pump vacuolar (V)-ATPase is the driving force that mediates the concentration of cationic drugs (weak bases) in the late endosome-lysosome continuum; secondary cell reactions include the protracted transformation of enlarged vacuoles into
Externí odkaz:
https://doaj.org/article/9ce5a29fc52d4ead9d757e0d490c1fcd
Autor:
Jean-Philippe Fortin, Marie-Thérèse Bawolak, Lajos Gera, Johanne Bouthillier, François Marceau, Hélène Bachelard, Guillaume Morissette, Xavier Charest-Morin
Publikováno v:
International immunopharmacology. 82
Bradykinin-related peptides, the kinins, are blood-derived peptides that stimulate 2 G protein–coupled receptors, the B1 and B2 receptors (B1R, B2R). The pharmacologic and molecular identities of these 2 receptor subtypes will be succinctly reviewe
Autor:
Johanne Bouthillier, Lajos Gera, François Marceau, Albert Adam, Caroline Roy, Marie-Thérèse Bawolak
Publikováno v:
Pharmacological Research. 64:528-534
Bradykinin (BK) is a vasoactive nonapeptide cleaved from circulating kininogens and that is degraded by angiotensin converting enzyme (ACE). It has been reported that the PR3 protease from human neutrophil releases an alternate peptide of 13 amino ac
Autor:
Jean-Philippe Fortin, François Marceau, Ritchie Audet, Thierry Sabourin, Guy Drapeau, Jean-François Larrivée, Luc Levesque, Denis Godin, Johanne Bouthillier, Guillaume Morissette, Marie-Thérèse Bawolak, Denis deBlois, Steeve Houle, Gérémy Abdull Koumbadinga, Lajos Gera, Eric Petitclerc
Publikováno v:
International Immunopharmacology. 10:1344-1353
The blood vessels are one of the important target tissues for the mediators of inflammation and allergy; further cytokines affect them in a number of ways. We review the use of the isolated blood vessel mounted in organ baths as an important source o
Autor:
Johanne Bouthillier, Lajos Gera, Albert Adam, Marie-Thérèse Bawolak, René C.-Gaudreault, François Marceau, Sébastien Fortin
Publikováno v:
British Journal of Pharmacology. 158:1375-1386
Background and purpose: A peptide bradykinin (BK) B2 receptor agonist partially resistant to degradation, B-9972, down-regulates this receptor subtype. We have used another recently described non-peptide agonist, compound 47a, as a tool to study furt
Publikováno v:
Drug Metabolism and Disposition. 37:2271-2274
The antiprotozoal agent quinacrine is a lipophilic cationic drug highly distributed to tissues. It has been used in the present experiments to examine whether the vacuolar and autophagic cytopathology induced by organic amines is independent from the
Publikováno v:
Toxicology and Applied Pharmacology. 229:320-331
The aims of this study were to investigate whether several histamine receptor agonists and antagonists are subjected to receptor-independent ion trapping into acidic organelles, and whether this sequestration influences their pharmacological or toxic
Autor:
Johanne Bouthillier, Xavier Charest-Morin, François Marceau, Michael Boivin-Welch, Alexandre Parks
Publikováno v:
PeerJ, Vol 3, p e1314 (2015)
PeerJ
PeerJ
The proton pump vacuolar (V)-ATPase is the driving force that mediates the concentration of cationic drugs (weak bases) in the late endosome-lysosome continuum; secondary cell reactions include the protracted transformation of enlarged vacuoles into
Autor:
Mark S. Robbins, François Marceau, Matthew L. Charles, Arvind Raghavan, Tadeusz Kolodka, Xavier Charest-Morin, Johanne Bouthillier, Melissa Jean
Publikováno v:
Pharmacology Research & Perspectives
Tissue kallikrein (KLK-1), a serine protease, initiates the release of bradykinin (BK)-related peptides from low-molecular weight kininogen. KLK-1 and the BK B2 receptor (B2R) mediate beneficial effects on the progression of type 2 diabetes and renal
Autor:
Sophie Otis, Jean-Philippe Fortin, Guillaume Morissette, Johanne Bouthillier, François Marceau
Publikováno v:
Journal of Pharmacology and Experimental Therapeutics. 311:1121-1130
The kinin B1 receptor (B1R) has attracted interest as a potential therapeutic target because this inducible G protein-coupled receptor is involved in sustained inflammation and inflammatory pain production. Compound 11 (2-{(2 R )-1-[(3,4-dichlorophen